诚达药业 reported revenue of ¥0.26B for the period ended 2026-06-30, +40.0% year on year. Net income was ¥0.00B, a 0.9% net margin on a 30.9% gross margin. The largest revenue line is 定制类产品和服务收入 at 51% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.26B | +40.0% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -82.4% |
| Gross margin | 30.9% | Net margin 0.9% |
| Revenue Q/Q | -0.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 定制类产品和服务收入 | ¥0.13B | 51.1% |
| 自主销售类产品收入 | ¥0.12B | 48.3% |
| 其他(补充) | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.18B | 69.1% |
| R&D | ¥0.02B | 8.9% |
| SG&A | ¥0.05B | 19.9% |
| Tax & other | ¥0.00B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.35B |
| Total liabilities | ¥0.25B |
| Shareholders' equity | ¥2.10B |
| Equity / assets | 89.3% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | 1886% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技 ・ 中汽股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies